IRLAB Therapeutics AB Employee Directory
Biotechnology ResearchVästra Götaland, Sweden11-50 Employees
IRLAB Therapeutics AB is a biotechnology company based in Gothenburg, Västra Götaland, Sweden, focused on discovering and developing treatments for Parkinson’s disease and other CNS disorders. Its pipeline includes two advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), both in Phase IIb trials, with Ipsen holding exclusive global rights to mesdopetam since 2021. The company operates its own discovery platform, Integrative Screening Process, and is pursuing additional candidates in preclinical stages, including IRL942 and IRL757 advancing toward Phase I. IRLAB is listed on Nasdaq Stockholm, reflecting its status as a publicly traded organization in the Swedish biopharma landscape. IRLAB focuses on addressing neurological symptoms associated with Parkinson’s disease and other CNS disorders. In 2026, the company presented results from its Phase IIb REACT-PD trial evaluating pirepemat's efficacy and safety in reducing falls among people with Parkinson’s disease at the AD/PD conference.
1-888-653-2347 
support@leadiq.com 
